Search This Blog

Monday, May 11, 2026

Intellia says FDA lifts clinical holds on Phase 3 nex-z ATTR trials

 

Intellia says FDA lifts clinical holds on Phase 3 nex-z ATTR trials, patient screening resumes

  • Intellia Therapeutics reported first-quarter 2026 results during its latest quarterly update.
  • Company said its cash runway now extends at least into 2028 following April’s equity offering.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)